CVSA
NYSE Covista Inc.$126.29 ↑ +0.81 (+0.65%) Trading Up from the previous close of $125.48, $0.50 below the day’s high of $126.79
- YTD change
- +26.81%
- vs 20-day SMA
- +1.65%
- vs 200-day SMA
- N/A
Price ranges
Price & Performance
+8.28 (+7.06%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 19.2% away from all-time highs of $156.26
- CVSA is up 27% since the beginning of the year
- CVSA is up 27% over the past 12 months
- CVSA is down 1% over the past 1 month
- 6% of all CVSA investors are betting against CVSA
- Number of investors short CVSA has gone up 9% versus last month
CVSA reads very good: short interest is rising month over month, the 12-month move is +26.0%.
- Previous minute
- +$0.04
- Last hour
- +$0.35
- Last 5 days
- +4.59%
- vs 8-day SMA
- +3.51%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Covista, Inc. engages in the provision of post-secondary education. It operates through the following segments: Chamberlain, Walden, and Medical and Veterinary. The Chamberlain segment offers degree and non-degree programs in the nursing and health professions postsecondary education industry. The Walden segment covers online certificates, bachelor's, master's, and doctoral degrees, including those in nursing, education, counseling, business, psychology, public health, social work and human services, public administration and public policy, and criminal justice. The Medical and Veterinary segment includes degree and non-degree programs in the medical and veterinary postsecondary education industry. The company was founded by Dennis J. Keller and Ronald L. Taylor in 1973 and is headquartered in Chicago, IL.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.